ArticlesEffect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients
References (28)
- et al.
Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial
Lancet
(1990) - et al.
Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestryramine, in the St Thomas' Atherosclerosis Regression Study (STARS)
Lancet
(1992) - et al.
Myocardial ischaemia, risk factors, and death from coronary heart-disease
Lancet
(1977) Enzyme methods for quantification of lipoprotein lipids
Methods Enzymol
(1986)- et al.
Precipitation methods for quantification of lipoproteins
Methods Enzymol
(1986) - et al.
Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials
Am J Cardiol
(1992) - et al.
The natural history of coronary atherosclerosis using quantitative angiography: implications for clinical trials of coronary regression
Am J Cardiol
(1993) - et al.
Frequency of low serum HDL in hospitalized patients with "desirable" total cholesterol levels
Am J Cardiol
(1991) - et al.
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Event trial (CARE)
Am J Cardiol
(1991) - et al.
Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol
J Am Coll Cardiol
(1994)
Influence of plaque configuration and stress distribution on fissuring or coronary atherosclerotic plaques
Lancet
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
N Engl J Med
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
JAMA
Cited by (177)
Compensatory enlargement of Ossabaw miniature swine coronary arteries in diffuse atherosclerosis
2015, IJC Heart and VasculatureThe effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
2014, AtherosclerosisCitation Excerpt :Another study performed in Korea revealed that the beneficial effects of statin therapy in AMI seem to vanish when LDL cholesterol is below 2.72 mmol/L (105 mg/dL) [12], which is consistent with the pretreatment concentration in our study. Furthermore, the beneficial changes of cholesterol lowering on regression of coronary atherosclerosis demonstrated by angiography are also directly related to the pretreatment level of LDL cholesterol, with little benefit occurring in patients with low LDL cholesterol levels [13]. Together, these results suggest that the reduction in the rate of coronary events with statins is influenced by the pretreatment level of LDL cholesterol and the benefit of statin therapy could decline or even vanish when LDL cholesterol is below a certain level.
Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: Still problematic after the primary publication
2012, Journal of Clinical LipidologyNonpharmacologic Treatment of Dyslipidemia
2009, Progress in Cardiovascular DiseasesCitation Excerpt :This 5-year study in men with a history of MI demonstrated a 26% reduction in total mortality and a 36% reduction in ischemic heart disease mortality. There have also been 7 clinical trials of niacin which assessed vascular anatomical end points (coronary artery lesions in 6, carotid Intimal Media Thickness [IMT] in 1).290-298 Five of these showed mean regression of the lesion dimensions from baseline.293-298
Statins for all: The new premed?
2009, British Journal of Anaesthesia